Rockley Photonics: Sensing the Future from Oxford

Rockley Photonics is a semiconductor company that designs and manufactures integrated silicon photonics chips, with a particular focus on health-sensing applications. Founded in 2013 by Andrew Rickman, a pioneer of the silicon photonics industry, the company is headquartered in Oxford and operates additional facilities in the United States. Rockley's core technology platform uses light, rather than electricity, to detect biomarkers in the human body, an approach that could reshape how chronic conditions like diabetes, cardiovascular disease and kidney health are monitored outside clinical settings.

The Technology

At its heart, Rockley builds photonic integrated circuits, sometimes called "chips of light." These devices guide infrared light through silicon waveguides on a chip, enabling spectroscopic analysis of substances such as blood. The company's full-stack approach means it designs not only the photonic chipsets but also the lasers, detectors, packaging, firmware and software needed to turn raw optical signals into clinically meaningful data. This vertical integration is unusual in the semiconductor world and gives Rockley a distinctive position among both chip companies and medtech startups.

The flagship sensing module is designed to be small enough to fit inside a wearable device, such as a smartwatch or a wrist-worn health monitor. Unlike conventional wearable sensors, which typically rely on green LED-based photoplethysmography (PPG) for heart rate, Rockley's platform uses mid-infrared and shortwave-infrared light to probe deeper into tissue and detect a wider range of analytes. The ambition is non-invasive, continuous monitoring of biomarkers that today require a blood draw or a visit to a clinic.

Origins and Leadership

Andrew Rickman founded Bookham Technology in the 1980s, one of the first companies to commercialise silicon photonics for telecommunications. That venture eventually became part of Lumentum, a major photonics supplier. Rickman brought decades of experience in scaling photonic systems from laboratory curiosity to mass production when he started Rockley. The company's early years were spent developing its platform technology and building intellectual property, much of it protected by a substantial patent portfolio covering chip design, packaging and sensing algorithms.

Rockley went public on the New York Stock Exchange in 2021 through a SPAC merger, a move that provided capital to accelerate product development and expand its team. The company has navigated the challenges common to pre-revenue deep-tech firms, including the need to balance long development timelines with investor expectations. Despite those pressures, Rockley has continued to refine its sensing platform and pursue partnerships with consumer electronics and healthcare companies.

Working at Rockley

The Oxford headquarters houses a multidisciplinary team that spans photonic chip design, analogue and digital electronics, firmware engineering, algorithm development, biomedical science and regulatory affairs. The culture reflects the realities of working at the frontier of multiple fields simultaneously. Engineers and scientists frequently cross traditional disciplinary boundaries, and problems rarely arrive neatly categorised.

"We are building something that doesn't exist yet, a clinical-grade sensor on a chip that sits on your wrist. That means every team, from optics to software, has to invent as they go."

Collaboration between hardware and software teams is not just encouraged but structurally necessary. A firmware engineer might spend a morning debugging a laser driver and an afternoon discussing signal-processing approaches with a data scientist. The company's relatively compact size means that individual contributors often have significant influence over design decisions, and the feedback loop between concept and prototype is short by semiconductor industry standards.

The Broader Landscape

Rockley operates at the convergence of several large, fast-moving markets. The global wearable health technology sector is projected to grow substantially over the coming decade, driven by ageing populations, rising chronic disease prevalence and consumer demand for real-time health data. Meanwhile, silicon photonics is finding new applications well beyond the data-centre interconnect market that first sustained it. Companies like Apple, Google and Samsung have all signalled interest in advanced health sensing for wearable devices, creating potential demand for the kind of integrated photonic modules Rockley develops.

Competition exists from both established semiconductor firms exploring photonic sensing and from medtech startups pursuing alternative non-invasive monitoring approaches. Rockley's differentiator is its full-stack capability, the ability to control the entire signal chain from photon generation through to processed health data, which in principle allows tighter optimisation and faster iteration than a company relying on third-party components.

Oxford and Beyond

Oxford provides a natural home for a company like Rockley. The city's deep bench of photonics expertise, cultivated over decades at the university and in surrounding research parks, creates a ready talent pool. Proximity to other advanced-technology firms in the Thames Valley corridor offers supply-chain and collaboration advantages. The company's US operations complement the Oxford base by providing closer access to key consumer electronics partners and clinical-trial infrastructure.

For those drawn to solving genuinely hard, multidisciplinary problems with real human impact, Rockley represents an unusual opportunity. The work is demanding, the technical challenges are formidable, and the stakes, measured in the potential to transform how millions of people manage their health, are high.